Is ResMed (RMD) overvalued or fairly valued?

MarketChacha shows ResMed's valuation in context — a trailing P/E of about 24.0, a forward P/E of about 18.6, a price-to-book of about 5.4 — alongside its revenue and profit growth and whether reported profit converts into operating cash, so you can judge value for yourself. MarketChacha does not issue ratings, price targets, or buy/sell advice.

Does ResMed's reported profit turn into cash?

Over 4 years, operating cash flow fully covered reported profit — earnings are backed by real cash. MarketChacha computes this cash-conversion check (1.17×) from reported figures — education, not a rating.

What is ResMed's revenue?

ResMed reported revenue of $5.7B for FY2026, with net profit of $1.5B, per official filings.

What is the share price of ResMed (RMD)?

ResMed last traded at $246.13 (+2.7% on the day), as of 10/20/2026 — a delayed quote shown for education, not investment advice.

ResMed

RMD · NYSE · Healthcare · United States

Snapshot

TickerRMD

ExchangeNYSE

SectorHealthcare

IndustryMedical Instruments & Supplies

CountryUnited States

Employees11,370

HeadquartersSan Diego, United States

Websitewww.resmed.com

Filings tracked17

About ResMed

ResMed Inc. engages in the digital health and cloud-connected medical devices business in the United States and internationally. It operates in two segments, Sleep and Breathing Health, and Residential Care Software. The company offers sleep recorders for the diagnosis and titration of sleep apnea in sleep clinics, hospitals, and at home, including ApneaLink Air, a portable diagnostic device that measures oximetry, respiratory effort, pulse, nasal flow, and snoring; NightOwl, a portable, cloud-connected, and disposable diagnostic device that measures AHI based on derived peripheral arterial tone, actigraphy, and oximetry; and EasyCare Tx, a sleep lab solution. It also provides AirView, a cloud-based system that enables remote monitoring and changing of patients' device settings; myAir, a personalized therapy management application for patients with sleep apnea that provides support, education, and troubleshooting tools for increased patient engagement and improved compliance; and connectivity module which provides a cellular connection between compatible ventilation devices and AirView system. In addition, the company offers Brightree solutions which are solutions and services for organizations in home medical equipment and pharmacy, orthotic and prosthetic, and home infusion; HEALTHCAREfirst solutions that offers electronic health record, software, billing and coding services, and advanced analytics that enables home health and hospice agencies to optimize clinical, financial and administrative processes; MatrixCare EHR software as a service solutions used by skilled nursing and senior living providers, life plan communities, and home health and hospice sectors; and MEDIFOX DAN software solutions that is used by residential care providers, such as home health and nursing home providers. ResMed Inc. was founded in 1989 and is headquartered in San Diego, California.

Who owns it

Insiders0.5%
Institutions72.9%
Public & other26.6%

1,347 institutional holders

Ownership breakdown from public market data.

Top holders

Blackrock Inc.8.76%
Vanguard Capital Management LLC6.74%
Vanguard Portfolio Management LLC5.63%
State Street Corporation4.75%
Geode Capital Management, LLC3.09%
Bank Of New York Mellon Corporation2.98%
First Trust Advisors LP1.62%
Invesco Ltd.1.47%

Largest institutional holders — last updated 6/30/2026.

Forensic scorecard

No major accounting red flags in the fundamentals we have — profit is backed by cash and returns look healthy.

Cash conversion1.17×

Over 4 years, operating cash flow fully covered reported profit — earnings are backed by real cash.

Net margin trend21.3% → 26.9%

Margin has expanded by about 5.7 points — the business is getting more profitable.

Return on equity23.1%

Latest ROE of 23.1% — capital is generating a healthy return.

Growth qualityrev 10% · PAT 19%

Profit growth is broadly tracking revenue growth — the earnings trend looks operational rather than one-off.

Computed by MarketChacha from reported figures (SEC XBRL). Education, not a rating or recommendation.

What's expected next

Next quarter

Rev $1.5B · EPS 3.03

Est. earnings growth +7.8%

Next fiscal year

Rev $6.2B · EPS 13.23

Est. earnings growth +9.5%

Analyst consensus estimates — not the company's own guidance.

New to these terms?

P/E ROE ROCE Margins Market cap

Browse the Learn hub →

Financials at a glance

Source: SEC XBRL

Annual

Quarterly · last 8

Revenue (FY2026)

$5.7B

Net margin

26.9%

ROE

23.1%

Revenue CAGR (3y)

+10.2%

Profit CAGR (3y)

+19.3%

EPS (FY2026)

10.43

Net profit (FY2026)

$1.5B

Ask MarketChacha about RMD

Get a cited, plain-English answer — the “why”, not just data. Finance research only, never buy/sell advice.

On MarketChacha

Posts about RMD

Why did ResMed (RMD) drop ~5% after a record quarter?c/usmarkets · 8/8/2026 · 1 comment▲ 1

Financials

Yearly

Period	Revenue	Net profit	EPS	Net margin	ROE
FY2026	$5.7B	$1.5B	10.43	26.9%	23.1%
FY2025	$5.1B	$1.4B	9.51	27.2%	23.5%
FY2024	$4.7B	$1.0B	6.92	21.8%	21.0%
FY2023	$4.2B	$897.6M	6.09	21.3%	21.7%

Quarterly

Period	Revenue	Net profit	EPS	Net margin
2026Q1	$1.4B	$398.7M	2.74	27.9%
2025Q4	$1.4B	$392.6M	2.68	27.6%
2025Q3	$1.3B	$348.5M	2.37	26.1%
2025Q1	$1.3B	$365.0M	2.48	28.3%
2024Q4	$1.3B	$344.6M	2.34	26.9%
2024Q3	$1.2B	$311.4M	2.11	25.4%
2024Q1	$1.2B	$300.5M	2.04	25.1%
2023Q4	$1.2B	$208.8M	1.42	18.0%
2023Q3	$1.1B	$219.4M	1.49	19.9%
2023Q1	$1.1B	$232.5M	1.58	20.8%

Figures as reported, in reporting currency. Source: SEC XBRL.

Filings & announcements

2026

8-K — Other events
SEC9/1/2026material
8-K — Auditor change, Executive/director change, Reg FD disclosure, Exhibits
SEC8/17/2026material
10-K filing
SEC8/13/2026
8-K — Results of operations, Other events, Exhibits
SEC8/6/2026material
8-K — Results of operations, Reg FD disclosure, Exhibits
SEC7/7/2026material
10-Q filing
SEC5/1/2026
8-K — Results of operations, Other events, Exhibits
SEC4/30/2026material
8-K — Executive/director change, Exhibits
SEC4/30/2026material
10-Q filing
SEC1/30/2026
8-K — Results of operations, Other events, Exhibits
SEC1/29/2026material

2025

8-K — Executive/director change, Shareholder vote results, Exhibits
SEC11/20/2025material
10-Q filing
SEC10/31/2025
8-K — Results of operations, Other events, Exhibits
SEC10/30/2025material
8-K — Executive/director change, Exhibits
SEC8/18/2025material
10-K filing
SEC8/8/2025
8-K — Executive/director change
SEC8/1/2025material
8-K — Results of operations, Other events, Exhibits
SEC7/31/2025material

In the news

Education and discussion only — not investment advice. Financials from official filings (SEC/BSE) and reported company statements; market figures (delayed market data) are delayed and shown for reference only. Verify with the linked sources before acting.